CN105796481A - Preparation method of dexamethasone calcium phosphate hydrogel - Google Patents
Preparation method of dexamethasone calcium phosphate hydrogel Download PDFInfo
- Publication number
- CN105796481A CN105796481A CN201610235978.5A CN201610235978A CN105796481A CN 105796481 A CN105796481 A CN 105796481A CN 201610235978 A CN201610235978 A CN 201610235978A CN 105796481 A CN105796481 A CN 105796481A
- Authority
- CN
- China
- Prior art keywords
- dexamethasone
- calcium phosphate
- preparation
- aqueous solution
- hydrogel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Provided is a preparation method of a dexamethasone calcium phosphate hydrogel. By mixing a dexamethasone sodium phosphate solution with a Ca<2+> containing aqueous solution, the dexamethasone sodium phosphate solution and the Ca<2+> containing aqueous solution can spontaneously form the dexamethasone calcium phosphate hydrogel in a self-assembly mode. The preparation method of the dexamethasone calcium phosphate hydrogel has the advantages of being simple in preparation, quick in hydrogel forming and accurate and controllable in drug loading capacity.
Description
Technical field
The present invention relates to field of pharmaceutical preparations, the preparation method being specifically related to a kind of dexamethasone calcium phosphate hydrogel.
Background technology
Dexamethasone is as a kind of antiinflammatory, Claritin, and the treatment of its first aid using medicine being mainly used as critical illness and all kinds of inflammation, is a kind of relatively safe steroid hormone medicine.In Present Domestic hospital, its medication popularity rate nearly 100%.The current whole world has had listed many glucocorticoid medicines, clinically mainly as aspect medications such as antiinflammatory, antiallergic, asthma, psoriasis and antieczematics.But dexamethasone long-term prescription can cause many bad instead, such as body weight increase, edema of lower limbs, the upper arm or ischemic necrosis of femoral head, hypokalemia syndrome, peptic ulcer or perforation, glaucoma, cataract etc..Nowadays, along with improving constantly of the increasingly extensive of medicinal application and people's living standard, the toxic and side effects of medicine is increasingly subject to people's attention.Thus how to realize medicine optimum curative effect (such as the local patholoic change such as eyes, skin) and lower pair effect in disease treatment by best pharmaceutical dosage form and administering mode and become focus and a difficult problem for everybody research.
In order to solve this difficult problem, it is developed the multiple dosage forms such as tablet, injection, gel, provides different selections for clinical disease treatment.Wherein gel preparations has character softness and can maintain definite shape, can pin medicine and moisture, be particularly suitable for the disease treatment at the position such as skin, eyes.But presently used dexamethasone gel preparation often has more adjuvant, such as excipient, preservative etc..This not only can increase pharmacy cost, also can introduce the relevant toxic and side effects of adjuvant simultaneously.
Summary of the invention
In order to overcome the defect of prior art, the preparation method that the invention provides a kind of dexamethasone calcium phosphate hydrogel, it is simple that the dexamethasone calcium phosphate hydrogel of preparation has preparation, and plastic is quick, the advantage that drug load is precisely controlled.
The technical solution that the present invention adopts is: the preparation method of a kind of dexamethasone calcium phosphate hydrogel, comprise the following steps: dexamethasone sodium phosphate is dissolved in water and makes the aqueous solution that concentration is 0.5-100mg/ml, add containing Ca in the dexamethasone sodium phosphate liquid of preparation2+Aqueous solution, until Ca in mixed solution2+Solubility is higher than till 1mg/ml, and mixing stands to dexamethasone sodium phosphate in mixed solution and containing Ca2+The molecule of aqueous solution be self-assembly of dexamethasone calcium phosphate hydrogel, obtain described dexamethasone calcium phosphate hydrogel.
The water that described dexamethasone sodium phosphate is dissolved in the water is distilled water.
The addition of described dexamethasone sodium phosphate aqueous solution with containing Ca2+The addition of aqueous solution be inversely proportional to.
Described containing Ca2+Aqueous solution be calcium chloride water or calcium gluconate aqueous solution.
The invention has the beneficial effects as follows: the preparation method that the invention provides a kind of dexamethasone calcium phosphate hydrogel, by by dexamethasone sodium phosphate solution and containing Ca2+Aqueous solution, make spontaneous to be between the two self-assembly of dexamethasone calcium phosphate hydrogel, it is simple that the preparation technology of this dexamethasone calcium phosphate hydrogel has preparation, and plastic is quick, the advantage that drug load is precisely controlled.
Accompanying drawing explanation
Fig. 1 is dexamethasone of the present invention Calcium phosphate gel-gel conversion figure.
Detailed description of the invention
Now the present invention is further described:
Wherein dexamethasone sodium phosphate solution with containing Ca2+Aqueous solution as it is shown in figure 1, dexamethasone sodium phosphate solution with containing Ca2+Amount of aqueous solution used be in above Fig. 1 curve and can be prepared by dexamethasone calcium phosphate hydrogel.
Embodiment 1
With distilled water for solution, at temperature 25 DEG C, prepare 1.5% dexamethasone calcium phosphate hydrogel:
Accurately weighing 3mg dexamethasone sodium phosphate and be dissolved in the distilled water of 1ml, add the calcium chloride water that isopyknic concentration is 2mg/ml, room temperature stands, and forms dexamethasone calcium phosphate hydrogel after about 2min.
Embodiment 2
With distilled water for solution, at temperature 25 DEG C, prepare 2.5% dexamethasone calcium phosphate hydrogel:
Accurately weighing 5mg dexamethasone sodium phosphate and be dissolved in the distilled water of 1ml, add the calcium chloride water that isopyknic concentration is 2mg/ml, room temperature stands, and forms dexamethasone calcium phosphate hydrogel after about 10sce.
Embodiment 3
With distilled water for solution, at temperature 25 DEG C, prepare 5% dexamethasone calcium phosphate hydrogel:
Accurately weighing 10mg dexamethasone sodium phosphate and be dissolved in the distilled water of 1ml, add the calcium chloride water that isopyknic concentration is 2mg/ml, room temperature stands, and forms dexamethasone calcium phosphate hydrogel immediately.
Embodiment 4
With distilled water for solution, at temperature 25 DEG C, prepare 10% dexamethasone calcium phosphate hydrogel:
Accurately weighing 20mg dexamethasone sodium phosphate and be dissolved in the distilled water of 1ml, add the calcium chloride water that isopyknic concentration is 2mg/ml, room temperature stands, and forms dexamethasone calcium phosphate hydrogel immediately.
The above is only the preferred embodiment of the present invention, and protection scope of the present invention is not limited merely to above-described embodiment, and all technical schemes belonged under thinking of the present invention belong to protection scope of the present invention.It should be pointed out that, for those skilled in the art, some improvements and modifications without departing from the principles of the present invention, these improvements and modifications also should be regarded as protection scope of the present invention.
Claims (4)
1. the preparation method of a dexamethasone calcium phosphate hydrogel, it is characterised in that comprise the following steps: dexamethasone sodium phosphate is dissolved in water and makes the aqueous solution that concentration is 0.5-100mg/ml, adds containing Ca in the dexamethasone sodium phosphate liquid of preparation2+Aqueous solution, until Ca in mixed solution2+Solubility is higher than till 1mg/ml, and mixing stands to dexamethasone sodium phosphate in mixed solution and containing Ca2+The molecule of aqueous solution be self-assembly of dexamethasone calcium phosphate hydrogel, obtain described dexamethasone calcium phosphate hydrogel.
2. the preparation method of a kind of dexamethasone calcium phosphate hydrogel according to claim 1, it is characterised in that the water that described dexamethasone sodium phosphate is dissolved in the water is distilled water.
3. the preparation method of a kind of dexamethasone calcium phosphate hydrogel according to claim 1, it is characterised in that the addition of described dexamethasone sodium phosphate aqueous solution with containing Ca2+The addition of aqueous solution be inversely proportional to.
4. the preparation method of a kind of dexamethasone calcium phosphate hydrogel according to claim 1, it is characterised in that described containing Ca2+Aqueous solution be calcium chloride water or calcium gluconate aqueous solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610235978.5A CN105796481A (en) | 2016-04-18 | 2016-04-18 | Preparation method of dexamethasone calcium phosphate hydrogel |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610235978.5A CN105796481A (en) | 2016-04-18 | 2016-04-18 | Preparation method of dexamethasone calcium phosphate hydrogel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105796481A true CN105796481A (en) | 2016-07-27 |
Family
ID=56460946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610235978.5A Pending CN105796481A (en) | 2016-04-18 | 2016-04-18 | Preparation method of dexamethasone calcium phosphate hydrogel |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105796481A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108478607A (en) * | 2018-04-26 | 2018-09-04 | 广西呈鸣生物科技有限公司 | A kind of preparation method of Herba Pileae Scriptae extract liposome hydrogel |
| WO2021042777A1 (en) * | 2019-09-03 | 2021-03-11 | 苏州百迈生物医药有限公司 | Multi-component gel sustained-release pharmaceutical composition for treatment of tumors |
| CN113952346A (en) * | 2021-11-23 | 2022-01-21 | 烟台大学 | Novel medicinal combined hydrogel for treating rheumatoid arthritis and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102125516A (en) * | 2010-01-13 | 2011-07-20 | 北京大学 | Thermo-sensitive in-situ gel pharmaceutical composition |
| CN102532263A (en) * | 2011-08-29 | 2012-07-04 | 南开大学 | Bi-component drug micromolecule hydrogel based on hexadecadrol and taxol and preparation method thereof |
| CN102850422A (en) * | 2012-09-10 | 2013-01-02 | 南开大学 | Dexamethasone small-molecular hydrogel drug delivery system and preparation method thereof |
-
2016
- 2016-04-18 CN CN201610235978.5A patent/CN105796481A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102125516A (en) * | 2010-01-13 | 2011-07-20 | 北京大学 | Thermo-sensitive in-situ gel pharmaceutical composition |
| CN102532263A (en) * | 2011-08-29 | 2012-07-04 | 南开大学 | Bi-component drug micromolecule hydrogel based on hexadecadrol and taxol and preparation method thereof |
| CN102850422A (en) * | 2012-09-10 | 2013-01-02 | 南开大学 | Dexamethasone small-molecular hydrogel drug delivery system and preparation method thereof |
Non-Patent Citations (5)
| Title |
|---|
| 刘克辛: "《临床药理学》", 31 January 2012, 清华大学出版社 * |
| 刘静: "葡萄糖酸钙注射液与地塞米松磷酸钠注射液联合使用存在配伍禁忌的观察与探讨", 《当代护士》 * |
| 叶桂兰等: "葡萄糖酸钙注射液与地塞米松磷酸钠注射液存在配伍禁忌", 《现代护理》 * |
| 尚仰震: "《物理化学及胶体化学》", 30 September 1961, 农业出版社 * |
| 张丹等: "葡萄糖酸钙注射液与地塞米松磷酸钠注射液配伍禁忌探讨", 《中外医学研究》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108478607A (en) * | 2018-04-26 | 2018-09-04 | 广西呈鸣生物科技有限公司 | A kind of preparation method of Herba Pileae Scriptae extract liposome hydrogel |
| WO2021042777A1 (en) * | 2019-09-03 | 2021-03-11 | 苏州百迈生物医药有限公司 | Multi-component gel sustained-release pharmaceutical composition for treatment of tumors |
| CN112516073A (en) * | 2019-09-03 | 2021-03-19 | 苏州百迈生物医药有限公司 | Multicomponent gel sustained-release pharmaceutical composition for treating tumor |
| CN113952346A (en) * | 2021-11-23 | 2022-01-21 | 烟台大学 | Novel medicinal combined hydrogel for treating rheumatoid arthritis and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105796481A (en) | Preparation method of dexamethasone calcium phosphate hydrogel | |
| Duems-Noriega et al. | Subcutaneous fluid and drug delivery: safe, efficient and inexpensive | |
| US20080299228A1 (en) | Topical compositions comprising a macromolecule and methods of using same | |
| CN106138129A (en) | A kind of Chinese medicine compound thermosensitive hydrogel agent treating oral ulcer disease | |
| CN111012737A (en) | Flurbiprofen sodium gel and preparation method thereof | |
| CN102836419B (en) | Iron protein succinylate oral solution and preparation method thereof | |
| WO2014118040A1 (en) | Extract from indigo tinctoria for the topical treatment and prophylaxis of skin disorders | |
| CN104887618A (en) | Temperature-sensitive sol | |
| CN107198677B (en) | Progesterone suspension type long-acting injection, preparation method thereof and progesterone suspension injection powder | |
| JPS5942649B2 (en) | Myasthenia gravis treatment agent | |
| CN107362151A (en) | A kind of calcitriol liquid hard capsule and preparation method thereof, application | |
| CN111388411A (en) | Temperature-sensitive in-situ gel for relieving rhinitis and preparation method thereof | |
| US10322142B2 (en) | Polymer matrix compositions comprising a high concentration of bio-fermented sodium hyaluronate and uses thereof | |
| CN102440957B (en) | Terlipressin acetate nasal cavity spray and preparation method thereof | |
| CN105213321A (en) | Medicinal-bathing particle agent of a kind of arteannuin or derivatives thereof and uses thereof | |
| CN104771405A (en) | Compound terbinafine preparation and applications thereof | |
| CN102283970A (en) | Oil-in-water type cyperus oil nano-emulsion and preparation method thereof | |
| CN101278895A (en) | Instant type gel preparation for eye and method of producing the same | |
| CN103751779A (en) | Poloxamer gel adjuvant for O-typed foot and mouth disease polypeptides | |
| TW201440783A (en) | Pharmaceutical composition comprising micafungin or the salts thereof | |
| CN109646438A (en) | The application of demethyl coclaurine or its hydrochloride in preparation treatment rhinitis drug | |
| CN102697703B (en) | Piroxicam gel preparation and preparation method thereof | |
| CN106309354A (en) | Nasal-delivery temperature-sensitive in-situ gel sustained-release preparation comprising ketorolac tromethamine | |
| CN104606226A (en) | Anti-bacterial inflammation-diminishing traditional Chinese medicine suppository as well as preparation method and quality control method thereof | |
| CN102526112B (en) | Sustained-release pearl clear-sighted eye drops and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160727 |